Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419829 | 0.85 | MAPT (0.54) | SIGMAR1 | |
| SCHEMBL5745400 | 0.83 | KCNJ1 (0.61) | KCNH2KCNJ1MAOASIGMAR1HTR2A | |
| SCHEMBL23377646 | 0.82 | HRH3 (0.68) | KCNH2KCNJ1MAOASIGMAR1HTR2A | |
| SCHEMBL23377845 | 0.82 | HRH3 (0.62) | KCNH2KCNJ1MAOASIGMAR1HTR2A | |
| SCHEMBL9629316 | 0.81 | HRH3 (0.71) | KCNH2KCNJ1MAOASIGMAR1HTR2A | |
| SCHEMBL1307577 | 0.81 | SIGMAR1 (0.79) | SIGMAR1SLC6A3 | |
| SCHEMBL24322699 | 0.80 | SLC6A3 (0.73) | TAAR1SIGMAR1HTR2ASLC6A4SLC6A3 | |
| SCHEMBL3600688 | 0.80 | HTR2A (0.57) | KCNH2HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL8804098 | 0.79 | MAOA (0.67) | KCNH2KCNJ1MAOASIGMAR1HTR2A | |
| SCHEMBL3599810 | 0.79 | SPHK1 (0.63) | KCNH2KCNJ1MAOAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | KCNH2 4773/4885KCNJ1 4699/4885MAOA 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.